CD274 and non-small cell lung carcinoma: The combination of TMB ≥10 mutations/Mb, PD-L1 > 50%, and NLR <5 appears to improve the prediction of ICB outcome in NSCLC patients compared to TMB ≥ 9.24 mutations/Mb alone (AUC 0.62 vs 0.74).